The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
FDA clears FT538, the first CRISPR-edited, iPSC-derived cell therapy, for investigation as a new drug in AML and MM
On May 20, 2020, the U.S. Food & Drug Administration (FDA) cleared FT538, the first CRISPR-edited, induced pluripotent stem cell...
May 27, 2020
COMy 2020 | Highlights from the oral abstract session
A summary of the session entitled ‘Oral Abstracts’, which took place during the 6th World Congresses on Controversies in Multiple Myeloma (COMy) meeting, held virtually on Friday 15 May, 2020.
May 27, 2020
What are the key diagnostic criteria for confirming MGUS?
During COMy 2020, Graham Jackson, Northern Institute for Cancer Research, UK, spoke to the Multiple Myeloma Hub. We asked: What are the key diagnostic criteria for confirming MGUS?
May 22, 2020
María-Victoria Mateos
" The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice. "